dpp 4 inhibitor and glp 1 receptor agonist combination GLP-1-RA DPP-4 inhibitors in the management of type 2 diabetes Mechanisms of dipeptidyl peptidase‐4 (DPP‐4)

However, clinicians should also be aware that some individuals receiving tirzepatide may experience gastrointestinal adverse events, which could possibly lead to discontinuation of treatment

Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, et al

Addressing these underlying metabolic problems may help restore regular ovulation and improve fertility

Briefing will be completed on February 25, 2025

Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects

Rare but serious risks (such as pancreatitis or gallbladder issues) will be discussed at your consultation so you can make an informed decision